| human | Q5 |
| P10949 | IRIS UNICAMPANIA author ID | 00013 |
| P496 | ORCID iD | 0000-0001-5617-9829 |
| P3829 | Publons author ID | 2317095 |
| P1053 | ResearcherID | A-8641-2016 |
| P1153 | Scopus author ID | 21935486600 |
| P69 | educated at | University Hospital Zurich | Q450139 |
| University of Campania "Luigi Vanvitelli" | Q3551649 | ||
| University of Naples Federico II | Q691851 | ||
| P108 | employer | University of Campania "Luigi Vanvitelli" | Q3551649 |
| P734 | family name | Vettori | Q21493523 |
| Vettori | Q21493523 | ||
| Vettori | Q21493523 | ||
| P735 | given name | Serena | Q854464 |
| Serena | Q854464 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | female | Q6581072 |
| Q60924682 | Anti-carbamylated protein antibodies and skin involvement in patients with systemic sclerosis: An intriguing association |
| Q54511770 | Association between a stromal cell-derived factor 1 (SDF-1/CXCL12) gene polymorphism and microvascular disease in systemic sclerosis. |
| Q34237586 | Association of circulating miR-223 and miR-16 with disease activity in patients with early rheumatoid arthritis. |
| Q51452981 | CXCL4 in undifferentiated connective tissue disease at risk for systemic sclerosis (SSc) (previously referred to as very early SSc). |
| Q42983684 | Clinical and subclinical atherosclerosis in systemic sclerosis: consequences of previous corticosteroid treatment. |
| Q41108942 | Clinical correlates of human leucocyte antigen (HLA)-G in systemic sclerosis |
| Q51684920 | Downregulation of miR-193b in systemic sclerosis regulates the proliferative vasculopathy by urokinase-type plasminogen activator expression. |
| Q45226627 | EUSTAR biobanking: recommendations for the collection, storage and distribution of biospecimens in scleroderma research |
| Q60641609 | Early Systemic Sclerosis: Analysis of the Disease Course in Patients With Marker Autoantibody and/or Capillaroscopic Positivity |
| Q60641610 | Early Systemic Sclerosis: Serum Profiling of Factors Involved in Endothelial, T-cell, and Fibroblast Interplay is Marked by Elevated Interleukin-33 Levels |
| Q39938323 | Early systemic sclerosis: assessment of clinical and pre-clinical organ involvement in patients with different disease features |
| Q33766384 | Early systemic sclerosis: marker autoantibodies and videocapillaroscopy patterns are each associated with distinct clinical, functional and cellular activation markers |
| Q36633414 | Early systemic sclerosis: short-term disease evolution and factors predicting the development of new manifestations of organ involvement |
| Q50016508 | Esophageal high-resolution impedance manometry alterations in asymptomatic patients with systemic sclerosis: prevalence, associations with disease features, and prognostic value |
| Q40469082 | Functional disability and its predictors in systemic sclerosis: a study from the DeSScipher project within the EUSTAR group. |
| Q34066564 | High IL-17E and low IL-17C dermal expression identifies a fibrosis-specific motif common to morphea and systemic sclerosis |
| Q52911127 | IL-22 capacitates dermal fibroblast responses to TNF in scleroderma. |
| Q40301472 | Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database |
| Q36153763 | Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study |
| Q38657993 | International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphos |
| Q37629606 | Longitudinal analysis of quality of life in patients with undifferentiated connective tissue diseases. |
| Q51693090 | Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): efficacy of maintenance immunosuppression in responders and non-responders. |
| Q40073055 | Mapping and predicting mortality from systemic sclerosis |
| Q59616331 | MiRs in RA: possible biomarkers and therapeutic targets |
| Q48560986 | N-terminal pro-brain natriuretic peptide is a strong predictor of mortality in systemic sclerosis |
| Q37609999 | Non-Hodgkin's lymphoma in systemic sclerosis: case and literature review |
| Q39762874 | Outcome of a glucocorticoid discontinuation regimen in patients with inactive systemic sclerosis |
| Q91529684 | Performance of a new quantitative computed tomography index for interstitial lung disease assessment in systemic sclerosis |
| Q45715684 | Peripheral T cells from patients with early systemic sclerosis kill autologous fibroblasts in co-culture: is T-cell response aimed to play a protective role? |
| Q35954658 | Polymorphism of immunoglobulin enhancer element HS1,2A: allele *2 associates with systemic sclerosis. Comparison with HLA-DR and DQ allele frequency |
| Q36687460 | Quality of life as measured by the short-form 36 (SF-36) questionnaire in patients with early systemic sclerosis and undifferentiated connective tissue disease |
| Q48617946 | Right atrial morphology and function in patients with systemic sclerosis compared to healthy controls: a two-dimensional strain study. |
| Q36093326 | Role of MicroRNAs in Fibrosis |
| Q51550147 | Serum CXCL4 increase in primary Sjögren's syndrome characterizes patients with microvascular involvement and reduced salivary gland infiltration and lymph node involvement. |
| Q36060142 | Subspecificities of anticentromeric protein A antibodies identify systemic sclerosis patients at higher risk of pulmonary vascular disease |
| Q40404296 | The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index |
| Q40183753 | The concept of early systemic sclerosis following 2013 ACR\EULAR criteria for the classification of systemic sclerosis. |
| Q33796186 | The cumulative number of micro-haemorrhages and micro-thromboses in nailfold videocapillaroscopy is a good indicator of disease activity in systemic sclerosis: a validation study of the NEMO score. |
| Q60641615 | The β-fibrinogen -455 G>A gene polymorphism is associated with peripheral vascular injury in systemic sclerosis patients |
| Q45364555 | Tissue Doppler imaging in systemic sclerosis: a 3-year longitudinal study |
| Q46987453 | Twelve-month azathioprine as maintenance therapy in early diffuse systemic sclerosis patients treated for 1-year with low dose cyclophosphamide pulse therapy. |
| Q60641619 | [Hypocomplementemia in systemic sclerosis] |
| Q60641616 | [Survival and death causes in 251 systemic sclerosis patients from a single Italian center] |
Search more.